Recent randomized trials, including EARLY TAVR, AVATAR, RECOVERY, and EVOLVED, suggest benefits of early aortic valve replacement (AVR) in asymptomatic severe aortic stenosis (AS).

Early AVR reduces stroke, heart failure hospitalizations, and cardiovascular events, with a trend toward improved survival.

The data support shifting from clinical surveillance to early intervention?